Tridek One
- Biotech or pharma, therapeutic R&D
Tridek-One is a spin-off from INSERM, pioneering a platform-based approach which leverages CD31 ITIM receptor agonism to modulate ITAM receptor activation for the treatment of a broad spectrum of autoimmune and inflammatory disorders.
We focus on the development of first-in-class bispecific antibodies targeting CD31 and cell-specific ITAM receptors, enabling the selective targeting of pathogenic immune cells.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}